Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemiaYishai Ofran, Avraham Frisch, Tsila Zuckerman et al.|Leukemia|2019Cited by 69
Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib TherapyOfrat Beyar‐Katz, Yuval Shaked, Marina Bersudsky et al.|Molecular Cancer Research|2019Cited by 34